{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:20:06Z","timestamp":1785943206640,"version":"3.56.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several studies have indicated that exposure to immune checkpoint inhibitors (ICIs) can enhance the efficacy of subsequent chemotherapy. Although combination chemotherapy with ICI has become a standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (AGC), its impact on the efficacy of taxane plus ramucirumab (RAM) remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed data from consecutive patients with HER2-negative AGC who had previously received oxaliplatin-based chemotherapy, with or without nivolumab, followed by taxane plus RAM between March 2015 and July 2024. Patients were categorized into two cohorts according to prior nivolumab exposure: cohort A (ICI-na\u00efve) and cohort B (ICI-exposed). Survival outcomes and toxicity were compared between the cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 191 patients were evaluated (158 in cohort A and 33 in cohort B). The median follow-up period (range) was 7.5 (0.2\u201379.4) months. The median overall survival was 7.8\u00a0months in cohort A and 7.6\u00a0months in cohort B [hazard ratio (HR), 1.24; 95% confidence interval (CI), 0.83\u20131.86; P\u00a0=\u00a0.293]. The median progression-free survival was 3.5 and 3.9\u00a0months, respectively (HR, 1.05; 95% CI, 0.72\u20131.55; P\u00a0=\u00a0.787). The overall response rate was 30.7% in cohort A and 15.4% in cohort B (P\u00a0=\u00a0.338). No new safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prior ICI exposure may not significantly affect the efficacy or safety of subsequent taxane plus RAM therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag073","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:30:34Z","timestamp":1776771034000},"page":"940-948","source":"Crossref","is-referenced-by-count":0,"title":["Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0914-2450","authenticated-orcid":false,"given":"Yusuke","family":"Miyajima","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9516","authenticated-orcid":false,"given":"Takeshi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Notsu","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Fushiki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotoe","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ohba","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-7504","authenticated-orcid":false,"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7949","authenticated-orcid":false,"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, Shizuoka 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026080510414251400_ref1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026080510414251400_ref2","year":"2024"},{"key":"2026080510414251400_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01698-4","article-title":"Japanese gastric cancer treatment guidelines 2025 (7th edition)","volume":"29","author":"Japanese Gastric Cancer Association","year":"2026","journal-title":"Gastric Cancer"},{"key":"2026080510414251400_ref4","volume-title":"Clinical Practice Guidelines in Oncology: Gastric Cancer","author":"National Comprehensive Cancer Network (NCCN)","year":"2026"},{"key":"2026080510414251400_ref5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026080510414251400_ref6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejca.2017.11.032","article-title":"A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer","volume":"91","author":"Bando","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026080510414251400_ref7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10637-019-00822-3","article-title":"Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis","volume":"38","author":"Ishikawa","year":"2020","journal-title":"Invest New Drugs"},{"key":"2026080510414251400_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103768","article-title":"Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT\/WJOG10617G): a randomised phase 2 trial in Japan","volume":"92","author":"Hirata","year":"2026","journal-title":"EClinicalMedicine"},{"key":"2026080510414251400_ref9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2026080510414251400_ref10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026080510414251400_ref11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026080510414251400_ref12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026080510414251400_ref13","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.2018.36.15_suppl.4065","article-title":"Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS)","volume":"36","author":"Kulangara","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080510414251400_ref14","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1158\/1538-7445.AM2019-2673","article-title":"Abstract 2673: association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)","volume":"79","author":"Lei","year":"2019","journal-title":"Cancer Res"},{"key":"2026080510414251400_ref15","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/esmoopen-2020-000775","article-title":"Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer","volume":"5","author":"Sasaki","year":"2020","journal-title":"ESMO Open"},{"key":"2026080510414251400_ref16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ijc.33559","article-title":"Outcomes on anti-VEGFR-2\/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma","volume":"149","author":"Kankeu Fonkoua","year":"2021","journal-title":"Int J Cancer"},{"key":"2026080510414251400_ref17","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"key":"2026080510414251400_ref18","doi-asserted-by":"publisher","first-page":"102071","DOI":"10.1016\/j.esmoop.2023.102071","article-title":"Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study","volume":"8","author":"Narita","year":"2023","journal-title":"ESMO Open"},{"key":"2026080510414251400_ref19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-018-0403-1","article-title":"Targeting VEGFR2 with ramucirumab strongly impacts effector\/activated regulatory T cells and CD8(+) T cells in the tumor microenvironment","volume":"6","author":"Tada","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026080510414251400_ref20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12885-025-13591-5","article-title":"Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1\/PD-L1 antibody (PADDLE)","volume":"25","author":"Hirano","year":"2025","journal-title":"BMC Cancer"},{"key":"2026080510414251400_ref21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"2026080510414251400_ref22","doi-asserted-by":"publisher","first-page":"100234","DOI":"10.1016\/j.esmoop.2021.100234","article-title":"A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care","volume":"6","author":"Shimozaki","year":"2021","journal-title":"ESMO Open"},{"key":"2026080510414251400_ref23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/sj.bjc.6604732","article-title":"Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?","volume":"99","author":"Catalano","year":"2008","journal-title":"Br J Cancer"},{"key":"2026080510414251400_ref24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2026080510414251400_ref25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026080510414251400_ref26","doi-asserted-by":"publisher","first-page":"28841","DOI":"10.1038\/s41598-025-13714-9","article-title":"Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab","volume":"15","author":"Matsumoto","year":"2025","journal-title":"Sci Rep"},{"key":"2026080510414251400_ref27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10120-025-01641-7","article-title":"An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study","volume":"28","author":"Kadowaki","year":"2025","journal-title":"Gastric Cancer"},{"key":"2026080510414251400_ref28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026080510414251400_ref29","doi-asserted-by":"publisher","first-page":"1358511","DOI":"10.3389\/fimmu.2024.1358511","article-title":"The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape","volume":"15","author":"Salnikov","year":"2024","journal-title":"Front Immunol"},{"key":"2026080510414251400_ref30","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1111\/cas.15057","article-title":"Immune infiltration profiling in gastric cancer and their clinical implications","volume":"112","author":"Ren","year":"2021","journal-title":"Cancer Sci"},{"key":"2026080510414251400_ref31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/onco.13680","article-title":"Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy","volume":"26","author":"Janowitz","year":"2021","journal-title":"Oncologist"},{"key":"2026080510414251400_ref32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026080510414251400_ref33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026080510414251400_ref34","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.18632\/oncotarget.23429","article-title":"Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"2026080510414251400_ref35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2026080510414251400_ref36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","article-title":"Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy","volume":"1","author":"Johnson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2026080510414251400_ref37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026080510414251400_ref38","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00262-023-03429-z","article-title":"Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations","volume":"72","author":"Shimoda","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026080510414251400_ref39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/940\/68482351\/hyag073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/940\/68482351\/hyag073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:41:51Z","timestamp":1785940911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/8\/940\/8703155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag073","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,5]]}}}